Lu T - Search Results

1

Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients.

Wu S, Zhang J, Chen S, Zhou X, Liu Y, Hua H, Qi X, Mao Y, Young KH, Lu T. Wu S, et al. Among authors: lu t. Ann Hematol. 2024 Aug;103(8):2877-2892. doi: 10.1007/s00277-024-05829-2. Epub 2024 Jun 6. Ann Hematol. 2024. PMID: 38842567

2

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.

Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, Gong QX, Wang Z, Young KH, Xu W, Zhang ZH, Li JY. Lu TX, et al. Oncotarget. 2015 Jul 30;6(21):18374-88. doi: 10.18632/oncotarget.4073. Oncotarget. 2015. PMID: 26158410 Free PMC article.

3

TP53 dysfunction in diffuse large B-cell lymphoma.

Lu TX, Young KH, Xu W, Li JY. Lu TX, et al. Crit Rev Oncol Hematol. 2016 Jan;97:47-55. doi: 10.1016/j.critrevonc.2015.08.006. Epub 2015 Aug 10. Crit Rev Oncol Hematol. 2016. PMID: 26315382 Review.

4

Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients.

Wang T, Ning K, Lu TX, Sun X, Jin L, Qi X, Jin J, Hua D. Wang T, et al. Among authors: lu tx. Cancer Sci. 2017 Mar;108(3):448-454. doi: 10.1111/cas.13150. Cancer Sci. 2017. PMID: 28032400 Free PMC article.

5

Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma.

Wu S, Zhou Y, Hua HY, Zhang Y, Zhu WY, Wang ZQ, Li J, Gao HQ, Wu XH, Lu TX, Hua D. Wu S, et al. BMC Cancer. 2018 Oct 19;18(1):997. doi: 10.1186/s12885-018-4914-4. BMC Cancer. 2018. PMID: 30340560 Free PMC article.

6

Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.

Lu TX, Wu S, Cai DY, Hong TT, Zhang Y, Gao HQ, Hua HY, Wu XH. Lu TX, et al. BMC Cancer. 2019 Jun 8;19(1):553. doi: 10.1186/s12885-019-5758-2. BMC Cancer. 2019. PMID: 31176361 Free PMC article.

7

CD5⁺MYC⁺ predicts worse prognosis in diffuse large B-cell lymphoma.

Lu TX, Wu S, Zhou XY, Zhang Y, Hong TT, Cai DY, Hua HY, Qi XW, Wu XH. Lu TX, et al. Exp Mol Pathol. 2020 Feb;112:104326. doi: 10.1016/j.yexmp.2019.104326. Epub 2019 Nov 9. Exp Mol Pathol. 2020. PMID: 31706988

8

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.

Pang Y, Lu T, Xu-Monette ZY, Young KH. Pang Y, et al. Among authors: lu t. Int J Mol Sci. 2023 Mar 13;24(6):5493. doi: 10.3390/ijms24065493. Int J Mol Sci. 2023. PMID: 36982568 Free PMC article. Review.

9

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.

Lu T, Zhang J, Xu-Monette ZY, Young KH. Lu T, et al. Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z. Exp Hematol Oncol. 2023. PMID: 37580826 Free PMC article. Review.

10

Prognostic Value of Combined LMR and CEA Dynamic Monitoring in Postoperative Colorectal Cancer Patients.

Chen S, Zhang J, Qian C, Qi X, Mao Y, Lu T. Chen S, et al. Among authors: lu t. J Inflamm Res. 2023 Sep 22;16:4229-4250. doi: 10.2147/JIR.S422500. eCollection 2023. J Inflamm Res. 2023. PMID: 37772275 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,764 results

Search Page

Filters